SEC Tracker
Get the app

Entera Bio ENTX

Entera Bio appoints new director

Item 5.02 Executive or director change, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Dr. Juan Camilo Arjona Ferreira appointed as Class II director effective Dec 1, 2026
  2. Haya Taitel steps down as director effective Dec 1, 2026
  3. Dr. Arjona Ferreira joins compensation committee
  4. Company issued press release on Oct 27, 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Entera Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Instil Bio TIL public float $83M, Jun 30, 2025
  2. Coherus Oncology CHRS public float $82M, Jun 30, 2025
  3. SAB Biotherapeutics SABS public float $77M, Jun 30, 2025
  4. Vor Biopharma VOR public float $76M, Jun 30, 2025
  5. Jasper Therapeutics JSPR public float $75M, Jun 30, 2025